Use of individualized starting dose and niraparib hematologic adverse event management costs in ovarian cancer.

Autor:	Graybill WS; Division of Gynecologic Oncology, Medical University of South Carolina, Charleston, SC 29425, USA., Vergote I; University Hospitals Leuven, Leuven Cancer Institute, and Belgium & Luxembourg Gynaecological Oncology Group (BGOG), Leuven, B912 3000, Belgium., Pothuri B; GOG Foundation and Laura & Isaac Perlmutter Cancer Center, NYU Langone Health, New York, NY 10016, USA., Anttila M; Kuopio University Hospital, Kuopio, Finland, and NSGO, Copenhagen, 9 70200, Denmark., O'Malley DM; The Ohio State University andthe James Comprehensive Cancer Center, Columbus, OH 43210, USA., Lorusso D; Humanitas San Pio X, Milan, Humanitas University, Rozzano, 20089, Italy., Haggerty AF; Hackensack Meridian Health, Hackensack, NJ 07601, USA., Fabbro M; Institut Régional du Cancer de Montpellier, Montpellier, and GINECO, Paris, 34298, France., Chan JK; California Pacific Medical Center Palo Alto Medical Foundation, Sutter Cancer Research Consortium, San Francisco, CA 94301, USA., Heitz F; AGO Study Group and Kliniken Essen-Mitte, Essen, and Charité - Universitätsmedizin Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Department of Gynaecology, Berlin, 12203, Germany., Willmott LJ; Arizona Center for Cancer Care, Phoenix, AZ 85027, USA., Bruchim I; Hillel Yaffe Medical Center, Hadera, Technion Institute of Technology, Haifa, 38100, Israel, & ISGO., Zhuo Y; Kadlec Hematology and Oncology Clinic, Richland, WA 99336, USA., Estévez-García P; Hospital Universitario Virgen del Rocío, Sevilla, and GEICO, Madrid, 41013, Spain., Monk BJ; GOG Foundation; Florida Cancer Specialists and Research Institute, West Palm Beach, FL 33401, USA., Denys H; Ghent University Hospital, Ghent, 9000, Belgium., Knudsen A; Odense University Hospital, Odense, 5000, Denmark., Tinker AV; BC Cancer Vancouver, and Department of Medicine, University of British Columbia, Vancouver, BC, V6T1Z1, Canada., Sánchez LM; Hospital Universitario 12 de Octubre & GEICO, Madrid, 28041, Spain., Provencher D; Centre Hospitalier de l'Université de Montréal, Université de Montréal and Institut du Cancer de Montréal, Montreal, QC, H3T1J4, Canada., Barretina-Ginesta MP; Medical Oncology Department, Institut Català d'Oncologia; Girona Biomedical Research Institute (IDIBGI-CERCA), Girona University, Girona, Spain, and GEICO, 08908, Spain., Hartman J; GSK, Philadelphia, PA 19112, USA., Booth DV; GSK, Durham, NC 27709, USA., González-Martín A; Medical Oncology Department, Program in Solid Tumours, CIMA, Cancer Center Clínica Universidad de Navarra, Madrid, and Grupo Español de Investigación en Cancer ginecológicO (GEICO), Madrid, 28027, Spain.
Jazyk:	angličtina
Zdroj:	Journal of comparative effectiveness research [J Comp Eff Res] 2025 Jan; Vol. 14 (1), pp. e240133. Date of Electronic Publication: 2024 Dec 06.
DOI:	10.57264/cer-2024-0133
Abstrakt:	Aim: To understand the impact of the niraparib individualized starting dose (ISD), compared with fixed starting dose (FSD), on the cost of hematologic adverse event (AE) management from a US payer perspective. Methods: The frequencies of grade ≥3 hematologic AEs that occurred in >1% of patients treated with niraparib were obtained from the primary analysis results of the phase III PRIMA/ENGOT-OV26/GOG-3012 trial. US unit costs for each grade ≥3 AE in the base case were obtained from the 2017 Agency for Healthcare Research and Quality Healthcare Cost and Utilization Project database; unit costs were adjusted to 2020 US dollars. AE management costs per patient were calculated by multiplying AE unit cost by the frequency of each AE by niraparib starting dose. Because AEs were assumed to occur independently of one another, costs were added to derive the total cost. Results: For niraparib, the estimated AE management cost per patient was lower for the ISD than the FSD for all hematologic AEs (FSD vs ISD: thrombocytopenia, $4701.87 vs $1921.89; anemia, $2784.00 vs $1760.59; platelet count decreased, $2103.47 vs $922.51; neutropenia, $2112.50 vs $1369.56; neutrophil count decreased, $1285.87 vs $770.38). The total mean calculated AE management cost per patient was $12,987.71 with the FSD and $6744.93 with the ISD. Conclusion: For niraparib, the cost of managing hematologic AEs in the US was reduced by almost half with the ISD compared with the FSD. The cost reduction and improvements in safety associated with the niraparib ISD support its use in clinical practice.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu